TY - GEN A1 - Jung, Friedrich A1 - Pietzsch, Jens T1 - Regulation of bone regeneration T2 - Clinical Hemorheology and Microcirculation Y1 - 2019 UR - https://content.iospress.com/articles/clinical-hemorheology-and-microcirculation/ch199101 U6 - https://doi.org/10.3233/CH-199101 SN - 1875-8622 SN - 1386-0291 VL - 73 IS - 3 SP - 379 EP - 380 ER - TY - GEN A1 - Krüger-Genge, Anne A1 - Köhler, Susanne A1 - Laube, Markus A1 - Haileka, Vanessa A1 - Lemm, Sandy A1 - Majchrzak, Karolina A1 - Kammerer, Sarah A1 - Schulz, Christian A1 - Storsberg, Joachim A1 - Pietzsch, Jens A1 - Küpper, Jan-Heiner A1 - Jung, Friedrich T1 - Anti-Cancer Prodrug Cyclophosphamide Exerts Thrombogenic Effects on Human Venous Endothelial Cells Independent of CYP450 Activation—Relevance to Thrombosis T2 - Cells N2 - Cancer patients are at a very high risk of serious thrombotic events, often fatal. The causes discussed include the detachment of thrombogenic particles from tumor cells or the adverse effects of chemotherapeutic agents. Cytostatic agents can either act directly on their targets or, in the case of a prodrug approach, require metabolization for their action. Cyclophosphamide (CPA) is a widely used cytostatic drug that requires prodrug activation by cytochrome P450 enzymes (CYP) in the liver. We hypothesize that CPA could induce thrombosis in one of the following ways: (1) damage to endothelial cells (EC) after intra-endothelial metabolization; or (2) direct damage to EC without prior metabolization. In order to investigate this hypothesis, endothelial cells (HUVEC) were treated with CPA in clinically relevant concentrations for up to 8 days. HUVECs were chosen as a model representing the first place of action after intravenous CPA administration. No expression of CYP2B6, CYP3A4, CYP2C9 and CYP2C19 was found in HUVEC, but a weak expression of CYP2C18 was observed. CPA treatment of HUVEC induced DNA damage and a reduced formation of an EC monolayer and caused an increased release of prostacyclin (PGI2) and thromboxane (TXA) associated with a shift of the PGI2/TXA balance to a prothrombotic state. In an in vivo scenario, such processes would promote the risk of thrombus formation. KW - cancer KW - cyclophosphamide KW - human umbilical vein endothelial cells KW - HUVEC KW - liver KW - cytochrome P450 enzymes (CYP) KW - thrombosis Y1 - 2023 UR - https://www.mdpi.com/2073-4409/12/15/1965 U6 - https://doi.org/10.3390/cells12151965 SN - 2073-4409 VL - 12 IS - 15 ER - TY - GEN A1 - Lemm, Sandy A1 - Köhler, Susanne A1 - Wodtke, Robert A1 - Jung, Friedrich A1 - Küpper, Jan-Heiner A1 - Pietzsch, Jens A1 - Laube, Markus T1 - Investigation of radiotracer metabolic stability in vitro with CYP-overexpressing hepatoma cell lines T2 - Cells Y1 - 2022 U6 - https://doi.org/10.3390/cells11152447 SN - 2073-4409 VL - 11 IS - 15 ER - TY - GEN A1 - Lemm, Sandy A1 - Köhler, Susanne A1 - Wodtke, Robert A1 - Jung, Friedrich A1 - Küpper, Jan-Heiner A1 - Pietzsch, Jens A1 - Laube, Markus T1 - Enabling insights into the cytochrome P450 isoform specific metabolism of radiotracers by CYP overexpressing hepatoblastoma cell lines T2 - Nuclear Medicine and Biology Y1 - 2022 SN - 1872-9614 IS - 108-109, Supplement  SP - S66 EP - S67 ER -